Related by context. Frequent words. (Click for all words.) 59 Phase IIa trial 56 Phase 2a clinical 56 unblinded 55 methylnaltrexone 55 Phase 2b study 55 Phase 2a trial 55 vandetanib 55 phase IIb 54 Phase IIa 54 Phase IIa clinical 54 darusentan 54 Phase IIb clinical 54 DSMB 53 PROMACTA 52 sustained virologic response 52 Phase 1b 52 phase 2a 52 Mylotarg 52 Phase 2b trial 52 clinical trial 52 dose escalation 52 Board DSMB 52 prespecified 52 eculizumab 52 Phase Ib 51 primary endpoint 51 dose escalation trial 51 Phase IIb trial 51 Phase 2a 51 motavizumab 51 midstage study 51 liver metastases 51 GVAX 50 eltrombopag 50 vicriviroc 50 LymphoStat B 50 Phase III clinical 50 composite endpoint 50 SPIRIT III 50 secondary endpoint 50 Phase IIb 50 Zerenex 50 lupus nephritis 50 mg dose 50 tolerated dose MTD 49 pharmacodynamics 49 clinical endpoints 49 PEG Interferon lambda 49 PXD# 49 Phase 1b clinical 49 evaluable patients 49 dosing regimens 49 primary endpoints 49 efficacy endpoints 49 daclizumab 49 COPAXONE R 49 Welchol 49 ASA# 49 castration resistant prostate cancer 49 vilazodone 49 denufosol 49 multicenter clinical 49 confirmatory Phase 3 48 pharmacodynamic 48 tofacitinib 48 randomized controlled clinical 48 HGS ETR1 48 Phase III clinical trials 48 dosing regimen 48 placebo controlled 48 non inferiority 48 secondary endpoints 48 Phase III trials 48 pivotal Phase 48 Secondary endpoints 48 talactoferrin 48 Phase III 48 CYT# 48 valopicitabine 48 Phase 2b clinical 48 bosentan 47 INCB# [002] 47 mcg kg 47 randomized clinical 47 vernakalant 47 dose limiting toxicities 47 tolerability 47 seroconversion 47 Empatic 47 HbA1c levels 47 pivotal Phase III 47 hepatotoxicity 47 ZYBRESTAT 47 investigational compound 47 dose escalation study 47 pharmacokinetic profile 47 primary efficacy endpoint 47 blinatumomab 47 FTY# 47 nonresponders 47 belinostat